Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy

Dermatitis. 2022 May-Jun;33(3):e25-e29. doi: 10.1097/DER.0000000000000814. Epub 2021 Dec 10.
No abstract available

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • COVID-19*
  • Dermatitis, Atopic* / chemically induced
  • Disease Progression
  • Humans
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • dupilumab